array:21 [ "pii" => "X2013251406020144" "issn" => "20132514" "doi" => " " "estado" => "S300" "fechaPublicacion" => "2006-08-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2006;26:426-32" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2576 "formatos" => array:3 [ "EPUB" => 212 "HTML" => 1842 "PDF" => 522 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699506020147" "issn" => "02116995" "doi" => " " "estado" => "S300" "fechaPublicacion" => "2006-08-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2006;26:426-32" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4149 "formatos" => array:3 [ "EPUB" => 243 "HTML" => 3231 "PDF" => 675 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Albuminuria y riesgo cardiovascular. Estudio Koral-Cardio" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "426" "paginaFinal" => "432" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Albuminuria and cardiovascular risk: results of the KORAL-CARDIO study" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.R. González-Juanatey, Eduardo Alegría Ezquerra, José Luis Zamorano Gómez, Vicente Bertomeu González, Olga Velasco Guijarro, Inmaculada" "autores" => array:1 [ 0 => array:1 [ "nombre" => "J.R. González-Juanatey, Eduardo Alegría Ezquerra, José Luis Zamorano Gómez, Vicente Bertomeu González, Olga Velasco Guijarro, Inmaculada" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251406020144" "doi" => " " "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251406020144?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699506020147?idApp=UINPBA000064" "url" => "/02116995/0000002600000004/v0_201502091329/X0211699506020147/v0_201502091329/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251406020179" "issn" => "20132514" "doi" => " " "estado" => "S300" "fechaPublicacion" => "2006-08-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2006;26:433-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2956 "formatos" => array:3 [ "EPUB" => 243 "HTML" => 2027 "PDF" => 686 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Cystatin C as a renal function estimator in advanced chronic renal failure stages" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "433" "paginaFinal" => "438" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "CISTATINA C COMO ESTIMADOR DE LA FUNCIÓN RENAL EN ESTADIOS AVANZADOS DE ENFERMEDAD RENAL CRÓNICA" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.V. Martín, S Barroso, O Herráez, F de Sande, F Caravaca" "autores" => array:1 [ 0 => array:1 [ "nombre" => "M.V. Martín, S Barroso, O Herráez, F de Sande, F Caravaca" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699506020171" "doi" => " " "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699506020171?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251406020179?idApp=UINPBA000064" "url" => "/20132514/0000002600000004/v0_201502091552/X2013251406020179/v0_201502091552/en/main.assets" ] "itemAnterior" => array:16 [ "pii" => "X2013251406019945" "issn" => "20132514" "estado" => "S300" "fechaPublicacion" => "2006-08-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2006;26:421-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2390 "formatos" => array:3 [ "EPUB" => 207 "HTML" => 1873 "PDF" => 310 ] ] "en" => array:6 [ "idiomaDefecto" => true "titulo" => "Cystatin C: Yes, but..." "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "421" "paginaFinal" => "425" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "CISTANINA C: SÍ, PERO..." ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "F. Caravaca" "autores" => array:1 [ 0 => array:1 [ "nombre" => "F. Caravaca" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:8 [ "pii" => "X0211699506019948" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699506019948?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251406019945?idApp=UINPBA000064" "url" => "/20132514/0000002600000004/v0_201502091552/X2013251406019945/v0_201502091552/en/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Albuminuria and cardiovascular risk: results of the KORAL-CARDIO study" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "426" "paginaFinal" => "432" ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.R. González-Juanatey, Eduardo Alegría Ezquerra, José Luis Zamorano Gómez, Vicente Bertomeu González, Olga Velasco Guijarro, Inmaculada" "autores" => array:1 [ 0 => array:1 [ "nombre" => "J.R. González-Juanatey, Eduardo Alegría Ezquerra, José Luis Zamorano Gómez, Vicente Bertomeu González, Olga Velasco Guijarro, Inmaculada" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Albuminuria y riesgo cardiovascular. Estudio Koral-Cardio" ] ] "pdfFichero" => "P-E-S-A1281-EN.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "es" => array:1 [ 0 => array:3 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec436480" ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "Introducción y objetivos: La presencia de albuminuria identifica a un grupo de hipertensos con mayor riesgo cardiovascular y renal y obliga a controlar mejor la presión arterial con fármacos que bloqueen el sistema renina-angiotensina. El objetivo del estudio KORAL-CARDIO fue determinar las características clínicas y de manejo de pacientes con hipertensión, albuminuria y cardiopatía no tratados previamente con inhibidores angiotensínicos. Pacientes y métodos: Se incluyen prospectivamente 2.711 pacientes (44% mujeres) de 64 años de media con hipertensión arterial, cardiopatía isquémica o hipertensiva o fibrilación auricular con positividad en la detección cualitativa de albuminuria. El 42% tenían además diabetes mellitus de tipo 2. Resultados: El 7,2% de los no diabéticos y el 12,7% de los diabéticos tenían macroalbuminuria; el 25% y el 35% respectivamente tenían índice de masa corporal de más de 30 kg/m2. Las complicaciones asociadas fueron: cardiopatía isquémica (22 y 39%), ictus (4 y 8%), fibrilación auricular (19 y 22%), hipercolesterolemia (42 y 53%), hipertensión de grado 3 (8% en ambos casos). Recibían tratamiento antihipertensivo monofármaco el 66% de los no diabéticos y el 63% de los diabéticos, y sólo el 7% triple terapia; otros tratamientos fueron: hipolipemiantes (41 y 57%) y antiagregantes (37 y 58% respectivamente). Conclusiones: Las complicaciones asociadas a la albuminuria en hipertensos con cardiopatías, diabéticos y no diabéticos, no tratados con inhibidores angiotensínicos son muy frecuentes. El grado de control tensional fue escaso en este grupo." ] "en" => array:1 [ "resumen" => "Background and objectives: Albuminuria is a marker of higher cardiovascular and renal risk in hypertension; it also indicates the need of a tighter control of blood pressure with drugs blocking the renin-angiotensin system. The objective of the KORAL-CARDIO study was to assess the clinical picture and management of patients with hypertension and cardiac disease and albuminuria not previously treated with angiotensin inhibitors. Methods: A total of 2,711 hypertensive patients (44% female) with ischemic or hypertensive cardiopathy or atrial fibrillation and with a positive screening test for albuminuria was included. Type 2 diabetes was also present in 42%. Results: Macroalbuminuria was present in 7.2% of non diabetic and 12.7% of diabetic patients, respectively. Associated complications were: 25% and 35% body mass index over 30 kg/m2; 22% and 39% ischemic heart disease; 4% and 8% stroke; 19% and 22% atrial fibrillation; 42% and 53% high cholesterol levels; 8% and 8% grade 3 hypertension, for non-diabetics and diabetics respectively. Antihypertensive monotherapy was used in 66% of non-diabetics and in 63% of diabetics; only 7% of patients in both groups were treated with triple antihypertensive therapy. Conclusions: Cardiovascular complications are very frequently associated to albuminuria in patients with hypertension and heart disease not previously treated with angiotensin inhibitors. Blood pressure control was clearly inadequate in this group." ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000002600000004/v0_201502091552/X2013251406020144/v0_201502091552/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002600000004/v0_201502091552/X2013251406020144/v0_201502091552/en/P-E-S-A1281-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251406020144?idApp=UINPBA000064" ]
Journal Information
Full text access
Albuminuria and cardiovascular risk: results of the KORAL-CARDIO study
Albuminuria y riesgo cardiovascular. Estudio Koral-Cardio
Visits
5246
J.R. González-Juanatey, Eduardo Alegría Ezquerra, José Luis Zamorano Gómez, Vicente Bertomeu González, Olga Velasco Guijarro, Inmaculada
This item has received
Article information
Introducción y objetivos: La presencia de albuminuria identifica a un grupo de hipertensos con mayor riesgo cardiovascular y renal y obliga a controlar mejor la presión arterial con fármacos que bloqueen el sistema renina-angiotensina. El objetivo del estudio KORAL-CARDIO fue determinar las características clínicas y de manejo de pacientes con hipertensión, albuminuria y cardiopatía no tratados previamente con inhibidores angiotensínicos. Pacientes y métodos: Se incluyen prospectivamente 2.711 pacientes (44% mujeres) de 64 años de media con hipertensión arterial, cardiopatía isquémica o hipertensiva o fibrilación auricular con positividad en la detección cualitativa de albuminuria. El 42% tenían además diabetes mellitus de tipo 2. Resultados: El 7,2% de los no diabéticos y el 12,7% de los diabéticos tenían macroalbuminuria; el 25% y el 35% respectivamente tenían índice de masa corporal de más de 30 kg/m2. Las complicaciones asociadas fueron: cardiopatía isquémica (22 y 39%), ictus (4 y 8%), fibrilación auricular (19 y 22%), hipercolesterolemia (42 y 53%), hipertensión de grado 3 (8% en ambos casos). Recibían tratamiento antihipertensivo monofármaco el 66% de los no diabéticos y el 63% de los diabéticos, y sólo el 7% triple terapia; otros tratamientos fueron: hipolipemiantes (41 y 57%) y antiagregantes (37 y 58% respectivamente). Conclusiones: Las complicaciones asociadas a la albuminuria en hipertensos con cardiopatías, diabéticos y no diabéticos, no tratados con inhibidores angiotensínicos son muy frecuentes. El grado de control tensional fue escaso en este grupo.
Palabras clave:
Background and objectives: Albuminuria is a marker of higher cardiovascular and renal risk in hypertension; it also indicates the need of a tighter control of blood pressure with drugs blocking the renin-angiotensin system. The objective of the KORAL-CARDIO study was to assess the clinical picture and management of patients with hypertension and cardiac disease and albuminuria not previously treated with angiotensin inhibitors. Methods: A total of 2,711 hypertensive patients (44% female) with ischemic or hypertensive cardiopathy or atrial fibrillation and with a positive screening test for albuminuria was included. Type 2 diabetes was also present in 42%. Results: Macroalbuminuria was present in 7.2% of non diabetic and 12.7% of diabetic patients, respectively. Associated complications were: 25% and 35% body mass index over 30 kg/m2; 22% and 39% ischemic heart disease; 4% and 8% stroke; 19% and 22% atrial fibrillation; 42% and 53% high cholesterol levels; 8% and 8% grade 3 hypertension, for non-diabetics and diabetics respectively. Antihypertensive monotherapy was used in 66% of non-diabetics and in 63% of diabetics; only 7% of patients in both groups were treated with triple antihypertensive therapy. Conclusions: Cardiovascular complications are very frequently associated to albuminuria in patients with hypertension and heart disease not previously treated with angiotensin inhibitors. Blood pressure control was clearly inadequate in this group.
Full text is only aviable in PDF